MangoRx Review: It Names the Pharmacy, Then Takes Away Your Right to Another

And then it takes the choice away

Further down the same Terms document:

"If a Provider writes a prescription, you voluntarily and unconditionally waive your right to fill the prescription at any pharmacy of your choice."

MangoRx's FAQ answers that exact question twice, and both times says the opposite:

"Yes, individuals have the right to choose their own pharmacy, though results cannot be guaranteed outside the partner network."

"You have the right to choose your own pharmacy. However, results cannot be guaranteed for pharmacies outside of our network."

Two live first-party documents, contradicting each other on a patient's rights. The FAQ has the better of it: a prescription is written for a patient, and where it is filled is generally the patient's decision.

There is one more clause worth reading alongside those, also from the Terms:

"Certain of MangoRx's shareholders, directors, officers, employees, contractors or agents… may have a financial interest in one or more Third Parties, and may profit from your use of the Third Parties and/or the sale of Third-Party Goods and Services to you."

Disclosing that at all is to MangoRx's credit; most companies with the same arrangement say nothing. But put the three passages in order and the shape is clear. The company names the pharmacy. The company discloses that its own officers may profit from that pharmacy. The company then asks you to waive the right to use any other one — while its FAQ tells you that right exists.

The refunds that are and are not final

MangoRx's Terms say:

"We do not offer any refunds or returns. All sales are final."

Its FAQ says it twice more, and adds a reason:

"No, like all prescription medications governed by state and federal law, returns are not accepted and all sales are final."

MangoRx also publishes a refund policy page, live at `/refund-policy`, which grants refunds if a prescription is cancelled before it is filled, if a product arrives damaged or defective (within 7 days), if a return is due to MangoRx's error, and for telehealth visits under its cancellation policy — all within a 30-day window, with a disclosed $80 fee for cancelling a telehealth appointment inside 24 hours.

And its own FAQ, a few questions from the "all sales are final" answer, says: "What if I am declined treatment? The order will be canceled immediately and the amount captured at purchase will be refunded to the credit card."

So refunds exist. The "governed by state and federal law" framing is the part that grates: it presents a company policy as a legal impossibility, on a site that elsewhere publishes the policy under which it does in fact refund people.

What the copy gets right

It would be easy to let the documents colour the rest, and the rest genuinely deserves better.

MangoRx's sermorelin page says:

"Sermorelin is a peptide that signals the pituitary gland to stimulate your body's natural growth hormone release pathways rather than directly replacing growth hormone."

That is correct and unembellished. Its FAQ then does two things this site almost never sees.

First, it corrects the misunderstanding the product most invites: "No. Sermorelin is not a growth hormone. It works differently and is designed to support the body's natural processes." Companies usually let that confusion do the selling.

Second, asked how long it takes to work, it declines to say:

"Everyone is different. Some people report noticing changes sooner, while others may feel improvements gradually over time."

Compare a competitor in this same wave, whose FAQ tells the reader that "by the second month, fine lines and wrinkles start to decrease and noticeable improvements in hair and nail quality are seen", for the same molecule. One of those two answers is what honest uncertainty sounds like.

The NAD+ page is the same story. MangoRx calls it "a coenzyme your body naturally produces and uses every day" — correct — and volunteers that "NAD+ is not considered a traditional stimulant like caffeine". Another company in this wave sells the identical molecule under the heading "A peptide that signals your own pituitary gland".

None of that makes the products evidenced. It makes MangoRx the rare seller whose copy does not have to be argued with line by line.

What the registries actually hold

Sermorelin, at $185 a month, is the flagship. A ClinicalTrials.gov search returns no interventional record naming sermorelin as the intervention — none, at any phase, at any status. ¹ Six query forms were run, including "sermorelin acetate", "GHRH(1-29)" and "Geref", the brand under which it was once approved in the US and has since been withdrawn, plus a free-text pass over every field. The 27 studies returned are other molecules: tesamorelin, GHRH(1-44), or unspecified "GHRH" used for pituitary stimulation testing.

PubMed holds 24 records mentioning sermorelin and zero with the randomised-controlled-trial or clinical-trial publication type. ²

Because that is the kind of result that is usually a broken query, the same searches were run on three molecules that should be there. Tirzepatide: 158 registry records, 126 trial papers. Tesamorelin: 17 and 21. Bremelanotide: 10 and 11. The instrument works.

Injected NAD+, at $200 a month, has no completed randomised trial supporting a restoration-of-function claim either. ³ The substantial human literature is about oral precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules taken a different way.

MangoRx cites none of this, and it cites nothing else either. Across the whole site there is not one trial identifier, PubMed ID or study reference, for any product — including Slim, its semaglutide, where a large phase 3 programme genuinely exists.

"Clinically proven"

Which brings us to the one unhedged claim on the site. MangoRx's weight-loss page metadata reads:

"Lose weight with doctor-prescribed oral Semaglutide (GLP-1). Clinically proven, pharmacy-dispensed weight loss medication delivered discreetly."

Oral semaglutide does have phase 3 evidence — OASIS 4 tested the approved 25 mg oral product for weight management. ⁴ But Slim is recorded in MangoRx's own CMS as "Semaglutide + Vitamin B6", a compounded oral preparation, and no compounded oral semaglutide from any seller has been through a registered trial.

"Clinically proven" moves the approved product's evidence onto a preparation that has none. That is precisely the move FDA cited two other companies in this wave for, in warning letters about implying a compounded product carries a brand's standing. It is also conspicuously the only place on a carefully hedged site where the hedging stops.

Where you can actually buy it

MangoRx publishes a 42-state shipping list, which beats an unqualified "all 50 states". Eight states are absent from it: Alabama, Alaska, Arkansas, Mississippi, Washington, West Virginia, Wisconsin and Wyoming.

The lists do not agree with each other, though. MangoRx's ED and hair products are listed as not approved in nine states — including California, North Dakota, South Carolina and South Dakota, all four of which appear in the shipping list on the same FAQ page. Its testosterone product is listed as available in Washington, which is not in the shipping list at all.

And no state list is published for sermorelin or NAD+ specifically. A peptide buyer has no way to know which of the conflicting lists applies to them.

What this means if you are buying

If what you want is a company that will tell you who compounds your medication, MangoRx is one of the very few that does, and Epiq Scripts is a real, named, accredited pharmacy you can phone. That is worth a great deal, and it is why this review does not end where the Terms would put it.

Before you buy, read three documents against each other — the Terms, the FAQ and the refund policy — because they disagree about whether you may use another pharmacy and whether you can get your money back. Where they conflict, the FAQ is the one describing how prescriptions and refunds actually work.

On the products themselves: sermorelin has no human trial under any name, injected NAD+ has no completed trial, and MangoRx cites no study for either — though, to its credit, it does not claim one. The exception is Slim, where "clinically proven" describes a trial of a different product than the one you will receive.